about
Prediction of chemo-response in serous ovarian cancerGene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer.p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers.MUC16 (CA125): tumor biomarker to cancer therapy, a work in progressSquamous cell carcinoma of the vulva stage IA: long-term results.Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes.No association between FTO or HHEX and endometrial cancer risk.Cytokeratin staining of resected lymph nodes may improve the sensitivity of surgical staging for endometrial cancer.Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data.A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growthIn vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.Molecular determinants for lymph node metastasis in clinically early-stage endometrial cancer.Current issues in the management of endometrial cancer.Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility.Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations.Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel.Differentially expressed genes in preimplantation human embryos: potential candidate genes for blastocyst formation and implantation.Role of metadherin in estrogen-regulated gene expression.High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.Development of an intracellular, DNA methyltransferase-specific, and gene-specific assay for studying dynamic DNA methylation.BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatinThe BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin.Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines.The impact of multi-modal therapy on survival for uterine carcinosarcomas.Gene Expression Signature-Based Prediction of Lymph Node Metastasis in Patients With Endometrioid Endometrial Cancer.Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study.Placenta-Specific Protein 1 Expression in Human Papillomavirus 16/18-Positive Cervical Cancers Is Associated With Tumor Histology.Risk of occult inguinofemoral lymph node metastasis from squamous carcinoma of the vulva.Patterns of inguinal groin metastases in squamous cell carcinoma of the vulva.Comparison of gene expression patterns between avian and human ovarian cancersThe miR-503 cluster is coordinately under-expressed in endometrial endometrioid adenocarcinoma and targets many oncogenes, cell cycle genes, DNA repair genes and chemotherapy response genesA Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular VariablesPopulation Substructure Has Implications in Validating Next-Generation Cancer Genomics Studies with TCGAMolecular Characterization of Non-responders to Chemotherapy in Serous Ovarian CancerSmall bowel obstruction associated with post-hysterectomy vaginal vault prolapsePrimary squamous cell cancer of the vulva: radical versus modified radical vulvar surgeryLong-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulvaDifferential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behaviorInterval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy
P50
Q29248636-43DD3E8D-16DF-4047-A243-35D4AE598353Q30660745-C94424CD-6128-4685-AF69-FFECA028543EQ33598887-D4E8B2E7-E605-4B36-90DC-B365FBF04153Q33713506-B3DDC5B1-3291-44D1-BAFB-FD0F19034D84Q33808453-A1DB8965-AA87-439F-8F9E-4D8C4160145AQ33829174-00798977-AA5B-4ED4-AC18-FAC72C628C09Q34057961-FA543D9D-624B-4B23-812B-53888904A9BEQ35607767-9733D5CF-148B-4164-93B4-1563CBFBD842Q35670307-A7F6F77A-9878-407C-8DCF-5B9336018C9CQ35952832-A2FBDEC5-01EE-4F95-9134-96814B3271FAQ36072797-8EA5B258-B36C-4838-88C9-6A495E695536Q36502473-FC145150-2DF9-4333-92A1-E3C1FEF9197CQ37049748-31F3B748-BC5E-48F2-8ED5-F0056D5517A5Q37164415-270B391D-8E49-485E-A75F-007C8ACF373EQ37600696-A20E1B9B-630D-4645-8994-9A87423D1E22Q37694030-3716E3FD-4B88-433C-987E-CFC4BADFD533Q38292267-6418D8EC-DA2C-4464-8E1B-EB90E7E395C3Q38719595-6F7F4E30-2452-42DC-B7B7-0244A5C6E186Q38770214-20E595AD-0307-4C80-9B2E-F906E5218EA2Q39120093-84606884-88E0-45F0-8F52-B0B5B83BBCA8Q39392319-879A3298-1040-45DC-8258-A6970D4B1B4AQ39451781-8872C207-C09D-4749-8A3B-81DC6D337398Q40397013-595EB5FE-EF9E-4AB9-9C49-525F1307FFA8Q44121548-658F8DDF-3704-4746-AF0A-D7E545ABD968Q47385390-32BCDC0D-E6F2-460E-A793-5421AA849619Q47713155-972CF410-9856-478D-A818-B5554EB81BFDQ47827853-EF4CB72F-EA01-4795-AA01-3C6B2E7667AEQ53298104-1219B4DE-4A08-4DED-8585-709BBB391E88Q53563941-DDB97F35-CED0-458A-A9E4-7C1F3F1FEA16Q57436931-F262F33D-D70E-40A8-ADAC-5655B8588CB5Q58694641-3C08AC36-D240-4767-AF00-78C8FA84DE50Q64111729-C8F02CE6-5939-4A56-8278-5DFF0A6F3B75Q64115497-152F251F-2D58-444A-9607-894F60153253Q64121576-BBC60F94-5821-4E93-BB08-E6562BAF7F12Q73916662-15941776-4784-4D94-8CFE-2403C7FBAD6DQ77450409-2A649327-F17C-476E-A1C4-B5FC37F952E2Q81751935-F9A3DC30-8126-460D-9970-84FC398F7329Q91559355-0E0A2E5D-B8D2-4816-A539-8F19DE266E98Q93268108-CB2A2E1C-B0D1-4865-8F9F-59934DD9F0AD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jesus Gonzalez Bosquet
@ast
Jesus Gonzalez Bosquet
@en
Jesus Gonzalez Bosquet
@es
Jesus Gonzalez Bosquet
@nl
type
label
Jesus Gonzalez Bosquet
@ast
Jesus Gonzalez Bosquet
@en
Jesus Gonzalez Bosquet
@es
Jesus Gonzalez Bosquet
@nl
prefLabel
Jesus Gonzalez Bosquet
@ast
Jesus Gonzalez Bosquet
@en
Jesus Gonzalez Bosquet
@es
Jesus Gonzalez Bosquet
@nl
P106
P1153
6602637763
6603632314
P21
P31
P496
0000-0002-2079-4528